Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.

Cancer science - 1 Aug 2022

Hu Dianxing, Guo Ensong, Yang Bin, Qin Xu, Fu Yu, Fan Junpeng, Zhuang Xucui, Yao Qianqian, Lu Funian, Li Wenting, Xiao Rourou, Wu Xue, Yang Xiaohang, Wang Zizhuo, Liu Chen, You Lixin, Zang Rongyu, Zhou Qi, Zhao Weidong, Chen Gang, Sun Chaoyang

Abstract excerpt

Although resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) has gradually become a major challenge in the maintenance therapy for high-grade serous ovarian carcinoma (HGSOC), there are no universal indicators for resistance monitoring in patients. A key resistance mechanism to PARPi is the restoration of homologous recombination repair (HRR), including BRCA reversion mutations and changes in DNA damage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell-Free Nucleic Acids
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to PARP inhibition in cancer therapy

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35661486
DOI: 10.1111/cas.15456
PMCID: PMC9357630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.PMID 35661486Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell LinesSemantic proximity Read ↗

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.Semantic proximity Read ↗

PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reportsSemantic proximity Read ↗

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionSemantic proximity Read ↗

Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA -Mutated Ovarian CancerSemantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.Semantic proximity Read ↗

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Semantic proximity Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaSemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.